GlassScriptPhysician profile
Prashant K Parekh
NPI 1568705788
$10,526.22
in general payments reported to CMS, 2019-2025
38 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,013 · 2020: $493 · 2021: $1,498 · 2022: $2,175 · 2023: $1,714 · 2024: $1,449 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,346.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,150.19 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $1,135.54 | 2019-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $1,021.86 | 2020-2025 | Acthar |
| Alcon Vision LLC | $722.15 | 2022-2025 | Clareon, Simbrinza, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $669.59 | 2022-2025 | Vyzulta, Miebo, Prolensa |
| Sun Pharmaceutical Industries INC. | $538.72 | 2020-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $484.55 | 2019-2023 | |
| Abbvie INC. | $465.01 | 2022-2025 | |
| Allergan, INC. | $407.76 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $373.11 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $321.17 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $311.53 | 2023-2025 | Syfovre |
| Astellas Pharma US INC | $283.10 | 2023-2025 | Izervay |
| Omeros Corporation | $280.34 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $233.44 | 2023-2024 | Omidria, Rayone Aspheric, Rayone Emv |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $226.42 | 2021-2025 | |
| Horizon Therapeutics Plc | $225.31 | 2019-2023 | Tepezza |
| Oyster Point Pharma, INC. | $209.59 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $205.06 | 2020-2021 | |
| Harrow Eye, LLC | $186.71 | 2024-2025 | Vevye |
| Genentech USA, INC. | $173.65 | 2023-2025 | Vabysmo |
| Carl Zeiss Meditec, INC. | $134.47 | 2019 | |
| Halozyme INC | $121.66 | 2023-2025 | Hylenex Recombinant |
| Alimera Sciences, INC. | $94.20 | 2019-2022 | |
| Eyepoint US, INC. | $68.64 | 2019-2022 | |
| Sight Sciences, INC. | $66.24 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Dompe US, INC. | $62.52 | 2020-2022 | |
| Thea Pharma INC. | $54.22 | 2024-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $51.89 | 2020-2021 | |
| Glaukos Corporation | $47.94 | 2025 | Idosetr |
| Eyevance Pharmaceuticals LLC | $43.25 | 2021-2022 | |
| Immunocore Limited | $30.33 | 2023 | Kimmtrak |
| Merz Pharmaceuticals, LLC | $26.84 | 2023 | Xeomin |
| Dutch Ophthalmic, USA | $26.44 | 2022 | |
| Ani Pharmaceuticals, INC. | $24.27 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $21.54 | 2025 | Tepezza |
| Quidel Corporation | $14.04 | 2022 | |
| Spark Therapeutics, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Parekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.